Cancer Research Consortium of West Michigan

COG-ACNS1721: A Phase 2 Study of Veliparib (ABT-888, IND # 139199) and Local Irradiation, Followed by Maintenance Veliparib and Temozolomide, in Patients with Newly Diagnosed High-Grade Glioma (HGG) without H3 K27M or BRAFV600 Mutations 

Patients must be ≥ 3 years and ≤ 25 years of age at the time of enrollment on Step 0.

Patients >21 years must be IDH mutant.

Note: At the time of ACNS1721 Step 1 enrollment, patients will be stratified and age is a factor.

COG-ACNS1723: A Phase 2 Study of Dabrafenib (NSC# 763760) with Trametinib (NSC# 763093) after Local Irradiation in Newly-Diagnosed BRAFV600-Mutant High-Grade Glioma (HGG) (IND# 145355)

Patients must be ≥ 3 years and ≤ 25 years of age at the time of enrollment on Step 0.

COG-ACNS1831: A Phase 3 Randomized Study of Selumetinib (IND # 77782) versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG)

Patients must be ≥ 2 years and ≤ 21 years at the time of enrollment.

COG-ACNS1422: A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients

Age - Patients must be greater than or equal to 3 years and less than 22 years of age at the time of enrollment on ACNS1422 Step 0.

COG ANBL00B1: Neuroblastoma Classification Biology Studies. All newly diagnosed patients with suspected neuroblastoma, suspected ganglioneuroblastoma, or suspected ganglioneuroma/maturing subtype seen at COG institutions are eligible for this study. 

COG-ACCL16N1CD: Documentation and Delivery of Guideline-Consistent Treatment in Adolescent and Young Adult AYA Acute Lymphoblastic Leukemia ALL

COG ALTE03N1: Key Adverse Events after Childhood Cancer. Diagnosis of primary cancer at age 21 or younger, irrespective of current age.

COG-AHEP1531: Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)

Age: Patients must be ≤ 30 years of age at the time of diagnosis

COG AREN03B2: Renal Tumors Classification, Biology, and Banking Study. Patients must be < 30 years old at the time of diagnosis. TEMPORARY CLOSURE

A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors

Age:

1. Low Risk Stratum (Stage I Ovarian Immature Teratoma and Stage I Malignant GCT (all sites))
   Patients must be < 50 years of age at enrollment.
2. Standard Risk 1
   Patient must be < 11 years of age at enrollment.
3. Standard Risk 2
   Patients must be ≥ 11 and < 25 years of age at enrollment.

COG-AGCT1532: A Randomized Phase 3 Trial of Accelerated versus Standard BEP Chemotherapy for Patients with Intermediate and Poor-risk Metastatic Germ Cell 

Age ≥ 11 years and ≤ 45 years on the date of randomization

COG AALL1631: International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Ph+ ALL Testing Imatinib in Combination with Two Different Cytotoxic Chemotherapy Backbone

Age:  > 1 year and < 21 years at ALL diagnosis

COG-AALL1521: A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway–Mutant Acute Lymphoblastic Leukemia 

Age ≥ 1 year and ≤ 21 years at time of leukemia diagnosis.

COG-AALL1621: A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518, IND# 133494) in Children and Young Adults with Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL) TEMPORARY CLOSURE

Patients must be ≥1 year and < 22 years of age at the time of enrollment.

COG-ACCL16N1CD: Documentation and Delivery of Guideline-Consistent Treatment in Adolescent and Young Adult AYA Acute Lymphoblastic Leukemia ALL

COG AALL1731: A Phase 3 Trial Investigating Blinatumomab (IND# 117467, NSC# 765986) in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B-Lymphoblastic Lymphoma (B-LLy)

Patients must be ≥ 365 days and < 10 years of age (B-ALL patients without DS)

Patients must be ≥ 365 days and ≤ 31 years of age (B-ALL patients with DS)

Patients must be ≥ 365 days and ≤ 31 years of age (B-LLy patients with or without DS) 

COG-AALL1732: A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-Lly

Patients must be > 365 days and < 25 years of age

A PHASE III, RANDOMIZED STUDY OF NIVOLUMAB (OPDIVO) PLUS AVD OR BRENTUXIMAB VEDOTIN (ADCETRIS) PLUS AVD IN PATIENTS (AGE >/= 12 YEARS) WITH NEWLY DIAGNOSED ADVANCED STAGE CLASSICAL HODGKIN LYMPHOMA

COG ANHL12P1: A Randomized Phase 2 Trial of Brentuximab Vedotin or Crizotinib in Combination with Chemotherapy for Newly Diagnosed Patients with Anaplastic Large Cell Lymphoma (ALCL). TEMPORARY CLOSURE

Patient must be < 22 years of age.

A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors

Age:

1. Low Risk Stratum (Stage I Ovarian Immature Teratoma and Stage I Malignant GCT (all sites))
   Patients must be < 50 years of age at enrollment.
2. Standard Risk 1
   Patient must be < 11 years of age at enrollment.
3. Standard Risk 2
   Patients must be ≥ 11 and < 25 years of age at enrollment.

Project:EveryChild A Registry, Eligibility Screening, Biology and Outcome Study

Subjects must be ≤ 25 years of age at time of original diagnosis, except for patients who are being screened specifically for eligibility onto a COG (or COG participating NCTN) therapeutic study, for whom there is a higher upper age limit.

COG ALTE03N1: Key Adverse Events after Childhood Cancer. Diagnosis of primary cancer at age 21 or younger, irrespective of current age.

COG ALTE05N1: Umbrella Long-term Follow-up Protocol. Only available to patients already enrolled on a COG intervention protocol.

COG ANBL00B1: Neuroblastoma Classification Biology Studies. All newly diagnosed patients with suspected neuroblastoma, suspected ganglioneuroblastoma, or suspected ganglioneuroma/maturing subtype seen at COG institutions are eligible for this study. 

COG ANBL1531: A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Intensive Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma (NBL) (IND# 134379)

Age - Patient must be ≥ 365 days and ≤ 30 years of age at diagnosis.

COG-ARST1431: A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating with Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864, IND# 122782) in Patients with Intermediate Risk (IR) Rhabdomyosarcoma (RMS) 

Feasibility Phase: Patients must be < 21 years of age at the time of enrollment.
Efficacy Phase: Patients must be ≤ 40 years of age at the time of enrollment.